Concepedia
Statistics
Publications
10
Citations
584
H-Index
Active since
1992
Affiliations
Experimental Station(Current)
Incyte (United States)
DuPont (United States)
Merck & Co., Inc., Rahway, NJ, USA (United States)
David Meloni is an author at Experimental Station specializing in pharmacology, natural sciences, and medicinal chemistry.
Top concepts
PharmacologyDrug DiscoveryNatural SciencesMedicinal ChemistryMedicineBiochemistryPharmacotherapyBiomolecular EngineeringChemistryImmunology
Publications per year
1992–2011
Efficient Synthesis of Losartan, A Nonpeptide Angiotensin II Receptor Antagonist
Robert D. Larsen, Anthony O. King, Cheng‐Yu Chen et al. · The Journal of Organic Chemistry · 1994 · 191 citations
Cardiovascular Pharmacology, Altmetric Attention Score, Peptide Science +17
Enantioselective Synthesis of Janus Kinase Inhibitor INCB018424 via an Organocatalytic Aza-Michael Reaction
Qiyan Lin, David Meloni, Yongchun Pan et al. · Organic Letters · 2009 · 167 citations
Engineering, Organic Chemistry, Chemistry +16
Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist
Chu‐Biao Xue, Hao Feng, Ganfeng Cao et al. · ACS Medicinal Chemistry Letters · 2011 · 48 citations · Full text
Chemotaxis Activity, Molecular Pharmacology, Potent Human Ccr2 +13
Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist
Chu‐Biao Xue, Anlai Wang, Qi Han et al. · ACS Medicinal Chemistry Letters · 2011 · 45 citations · Full text
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2
Chu‐Biao Xue, Anlai Wang, David Meloni et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 41 citations · Full text
Translational Pharmacology, Functional Selectivity, Medicine +7
1–5 of 10